Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States
Sponsor: Bausch Health Americas, Inc.
This PHASE3 trial investigates Diarrhea and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2019 — Dec 2019 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .